Modulators of the relaxin receptor 1

US10125112B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10125112-B2
Application numberUS-201615247438-A
CountryUS
Kind codeB2
Filing dateAug 25, 2016
Priority dateMay 4, 2012
Publication dateNov 13, 2018
Grant dateNov 13, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R 1 , and R 2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound or pharmaceutically acceptable salt thereof having the formula where: R 10 and R 21 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, mono- and di-(C 1 -C 2 alkyl)amino-, a C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy; R 20 is NO 2 , CN, C 2 -C 10 haloalkyl, C 1 -C 10 haloalkoxy, —SR 7 , —SOR 7 , or —SO 2 R 7 , where R 7 is C 1 -C 10 carbhydryl or C 1 -C 10 haloalkyl; and R 3 is cyclohexyl. 2. A method for therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1, the method comprising administering to a mammal in need thereof an effective amount of a compound or salt of claim 1 , wherein the facet of mammalian health is heart failure. 3. A compound or salt of the formula wherein R 2 is selected from:

Assignees

Inventors

Classifications

  • Thiophene-2-carboxylic acid · CPC title

  • with a four-membered ring · CPC title

  • having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring · CPC title

  • Adamantanes · CPC title

  • linked by a carbon chain containing aromatic rings · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10125112B2 cover?
Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R 1 , and R 2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for …
Who is the assignee on this patent?
The Us Secretary Department Of Health And Human Service, The Florida International Univ Board Of Trustees, Us Health
What technology area does this patent fall under?
Primary CPC classification C07D333/38. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).